Brain Delivery of Curcumin Using Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Preparation, Optimization, and Pharmacokinetic Evaluation

Malvajerd, Soroor Sadegh; Azadi, Amir; Izadi, Zhila; Kurd, Masoumeh; Dara, Tahereh; Dibaei, Maryam; Zadeh, Mohammad Sharif; Javar, Hamid Akbari; Hamidi, Mehrdad

doi:10.1021/acschemneuro.8b00510

Cited by 136 publications

(83 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the high hydrophobicity and low solubility of CUR in the water at acidic (or neutral) pH cause a major limitation for their wider therapeutic use [175]. It is well known that nanocarrier-based delivery systems can enhance the drug colloidal stability as well as its ability to cross the biological barriers and to reach the targeted regions [176,177]. For this reason, the employment of the nanocarriers as delivery systems for CUR represents a promising approach for the development of nano-platforms dedicated to the treatment of neurological disorders and brain diseases [177,178].…”

Section: Nanocarrier Formulations For Curcumin Deliverymentioning

confidence: 99%

“…Within these general issues, recent progress in drug delivery approaches stimulated the development of novel nanocarriers encapsulating CUR, such as polymer nanoparticles (and micelles), lipid-based (and liposome) nanocarriers, liquid crystalline nanocarriers (LCNs) andcyclodextrins ( Figure 6). systems can enhance the drug colloidal stability as well as its ability to cross the biological barriers and to reach the targeted regions [176,177]. For this reason, the employment of the nanocarriers as delivery systems for CUR represents a promising approach for the development of nano-platforms dedicated to the treatment of neurological disorders and brain diseases [177,178].…”

Section: Nanocarrier Formulations For Curcumin Deliverymentioning

confidence: 99%

“…More specifically, the entrapment efficiency of CUR was found to be 82% (in SLNs) and 94% (in NLCs). The pharmacokinetic studies (after intravenous administration of 4 mg/kg dose of CUR in rat) evidenced that the amount of CUR available in the brain in CUR-loaded NLCs (AUC0-t = 505.76 ng/g•h), was significantly higher than the CUR-loaded SLNs (AUC0-t = 116.31 ng/g•h) and the free CUR (AUC0-t = 0.00 ng/g•h) [176]. Furthermore, CUR-loaded SLNs were investigated to assess their efficacy in the treatment of the BV-2 microglial cells against LPS-induced neuroinflammation [208].…”

Section: Solid Lipid Nanoparticles and Nanostructured Lipid Carriersmentioning

confidence: 99%

See 2 more Smart Citations

Curcumin’s Nanomedicine Formulations for Therapeutic Application in Neurological Diseases

Salehi

Calina

Docea

et al. 2020

JCM

134

View full text Add to dashboard Cite

The brain is the body’s control center, so when a disease affects it, the outcomes are devastating. Alzheimer’s and Parkinson’s disease, and multiple sclerosis are brain diseases that cause a large number of human deaths worldwide. Curcumin has demonstrated beneficial effects on brain health through several mechanisms such as antioxidant, amyloid β-binding, anti-inflammatory, tau inhibition, metal chelation, neurogenesis activity, and synaptogenesis promotion. The therapeutic limitation of curcumin is its bioavailability, and to address this problem, new nanoformulations are being developed. The present review aims to summarize the general bioactivity of curcumin in neurological disorders, how functional molecules are extracted, and the different types of nanoformulations available.

show abstract

Section: Nanocarrier Formulations For Curcumin Deliverymentioning

confidence: 99%

Section: Nanocarrier Formulations For Curcumin Deliverymentioning

confidence: 99%

Section: Solid Lipid Nanoparticles and Nanostructured Lipid Carriersmentioning

confidence: 99%

See 1 more Smart Citation

Curcumin’s Nanomedicine Formulations for Therapeutic Application in Neurological Diseases

Salehi

Calina

Docea

et al. 2020

JCM

134

View full text Add to dashboard Cite

show abstract

“…In vivo: male Sprague−Dawley rats 6−8 weeks old, oral Enhanced curcumin brain uptake, Cur-NLCs enhance the absorption of brain curcumin more than 4-folds in comparison with Cur-SLNs [95]. AD Lipoprotein (LDL)-mimic nanostructured lipid carrier (NLC) modified with lactoferrin (Lf) and loaded with CU In vivo: Rat, oral Cellular uptake mediated by the Lf receptor, Permeability through the BBB and preferentially accumulation in the brain, Efficacy in controlling the damage associated with AD [96].…”

Section: Cns Disordersmentioning

confidence: 99%

Amphiphilic Nanocarrier Systems for Curcumin Delivery in Neurodegenerative Disorders

Rakotoarisoa¹,

Angelova²

2020

The Road From Nanomedicine to Precision Medicine

View full text Add to dashboard Cite

Neurodegenerative diseases have become a major challenge for public health because of their incurable status. Soft nanotechnology provides potential for slowing down the progression of neurodegenerative disorders by using innovative formulations of neuroprotective antioxidants like curcumin, resveratrol, vitamin E, rosmarinic acid, 7,8-dihydroxyflavone, coenzyme Q10, and fish oil. Curcumin is a natural, liposoluble compound, which is of considerable interest for nanomedicine development in combination therapies. The neuroprotective effects of combination treatments can involve restorative mechanisms against oxidative stress, mitochondrial dysfunction, inflammation, and protein aggregation. Despite the anti-amyloid and anti-tau potential of curcumin and its neurogenesis-stimulating properties, the utilization of this antioxidant as a drug in neuroregenerative therapies has huge limitations due to its poor water solubility, physico-chemical instability, and low oral bioavailability. We highlight the developments of soft lipid-and polymer-based delivery carriers of curcumin, which help improve the drug solubility and stability. We specifically focus on amphiphilic liquid crystalline nanocarriers (cubosome, hexosome, spongosome, and liposome particles) for the encapsulation of curcumin with the purpose of halting the progressive neuronal loss in Alzheimer's, Parkinson's, and Huntington's diseases and amyotrophic lateral sclerosis (ALS).

show abstract

“…The main objectives of this section were the experimental stages optimization in order to achieve the best imaginable analytical performance of the system, along with cost and time savings. In this study, a multi-purpose optimization method was used in order to optimize the preparation method of the polymeric mPEG-PCL nanoparticle [30,31]. Experimental design and statistical analysis have been accomplished with Design-Expert software (Version 7.0.2, State-Ease Minneapolis, MN, USA).…”

Section: Experimental Design and Optimizationmentioning

confidence: 99%

Oral delivery of indinavir using mPEG-PCL nanoparticles: preparation, optimization, cellular uptake, transport and pharmacokinetic evaluation

Kurd

Malvajerd

Rezaee

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

Self Cite

View full text Add to dashboard Cite

Introduction: Indinavir (IDV) is a potent HIV protease inhibitor used in the treatment of human immunodeficiency virus (HIV). IDV is a weak base with limited aqueous solubility in its unprotonated form; therefore, solubility of IDV in the gastrointestinal tract fluids is the rate-limiting step of its absorption and onset of action. However, in many cases, drugs are not absorbed well in the gastrointestinal tract; polymer nanoparticles were recognized as an effective carrier system for drug encapsulation and are now studied as a vehicle for oral delivery of insoluble compounds. Preparation of methoxy poly (ethylene glycol)-poly (e-caprolactone) (mPEG-PCL) nanoparticles is among the strategies to overcome low bioavailability of drugs with poor aqueous solubility. Materials and method: The structure of the copolymers was characterized using 1 H NMR, FTIR, DSC and GPC techniques. IDV loaded mPEG-PCL nanoparticles prepared by emulsification solvent evaporation method were optimized using D-optimal experimental design and were characterized by various techniques such as DLS, DSC, XRD, AFM and SEM. Using Caco-2 cells as a cellular model, we studied the cellular uptake and transport. Results: In vivo pharmacokinetic studies were performed in rats. The plasma AUC (0-t), t 1/2 and C max of IDV-mPEG-PCL NPs were increased by 5.30, 5.57 and 1.37 fold compared to the IDV solution, respectively. Conclusion: The results of this study are promising for the use of biodegradable polymeric nanoparticles to improve oral drug delivery.

show abstract

Brain Delivery of Curcumin Using Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Preparation, Optimization, and Pharmacokinetic Evaluation

Cited by 136 publications

References 86 publications

Curcumin’s Nanomedicine Formulations for Therapeutic Application in Neurological Diseases

Curcumin’s Nanomedicine Formulations for Therapeutic Application in Neurological Diseases

Amphiphilic Nanocarrier Systems for Curcumin Delivery in Neurodegenerative Disorders

Oral delivery of indinavir using mPEG-PCL nanoparticles: preparation, optimization, cellular uptake, transport and pharmacokinetic evaluation

Contact Info

Product

Resources

About